Alaunos Therapeutics vs Talphera
TCRT and TLPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TCRT and TLPH compare
Talphera is the larger company, worth 11 times as much as Alaunos Therapeutics ($47.0M against $4.1M).
Alaunos Therapeutics grew revenue faster over the last twelve months (−50.0% versus −100% for Talphera).
Talphera scores higher on the StockData Score (5 against 4 for Alaunos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TCRT | TLPH |
|---|---|---|
| Size and price | ||
| Market cap | $4.1M | $47.0M |
| Share price | $1.63 | $0.906 |
| Change, 1 year | −45.5% | −29.8% |
| Change, 5 years | −99.2% | −93.7% |
| Beta (5Y) | −0.42 | 0.61 |
| Employees | 1 | 12 |
| StockData Score | ||
| Total score | 4 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1380× | – |
| P/B | 6.4× | 4.4× (better) |
| Growth | ||
| Revenue growth (TTM) | −50.0% (better) | −100% |
| Revenue growth, 5Y average | – | −65.1% |
| Profitability | ||
| Operating margin | −135267% | – |
| Net margin | −133667% | – |
| Return on equity | −186% | −98.1% (better) |
| Return on invested capital | −489% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.77 | 3.19 (better) |
| Altman Z-score | −861.79 | −28.10 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 3.6% | 54.4% |
| Held by insiders | 69.8% | 46.8% |
| Insider net buying, 12 months | – | $304K |
| Short interest, % of float | 24.0% | 4.4% |
Go deeper
- TCRT stock overview
- TCRT income statement
- TCRT valuation and score
- TLPH stock overview
- TLPH income statement
- TLPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.